Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ATM | Q13315 | 1/20 | 0.40 |
| ▸ | PPM1D | O15297 | 1/20 | 0.32 |
| ▸ | VHL | P40337 | 1/20 | 0.31 |
| ▸ | ELOC | Q15369 | 1/20 | 0.31 |
| ▸ | ELOB | Q15370 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16053920 | 0.84 | PPM1D (0.36) | PPM1D | |
| SCHEMBL16053921 | 0.84 | PPM1D (0.36) | PPM1D | |
| SCHEMBL1710201 | 0.80 | ATM (0.40) | ATM | |
| SCHEMBL5006064 | 0.80 | PPM1D (0.36) | PPM1D | |
| SCHEMBL5006063 | 0.80 | PPM1D (0.36) | PPM1D | |
| SCHEMBL5006060 | 0.80 | PPM1D (0.36) | PPM1D | |
| SCHEMBL2449137 | 0.77 | ATM (0.40) | ATM | |
| SCHEMBL16324652 | 0.77 | BTK (0.41) | PPM1D | |
| SCHEMBL3835429 | 0.77 | ATM (0.42) | ATM | |
| SCHEMBL3747964 | 0.76 | PPM1D (0.35) | PPM1D |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2596790-A1 | Pim kinase inhibitors and methods of their use | Novartis AG (CH) | 2013-05-29 | — | — | EP | disclosed |
| US-8168794-B2 | Pim kinase inhibitors and methods of their use | NOVARTIS AG (CH) | 2012-05-01 | — | — | US | disclosed |
| US-20110195956-A1 | Heterocyclic Kinase Inhibitors | NOVARTIS AG (CH) | 2011-08-11 | — | — | US | disclosed |
| US-20100216839-A1 | Pim kinase inhibitors and methods of their use | NOVARTIS AG (CH) | 2010-08-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100216839-A1 | Pim kinase inhibitors and methods of their use | PIM1, PIM2, PIM3 | ATM 262/4885PPM1D 488/4885VHL 380/4885 |
| US-20110195956-A1 | Heterocyclic Kinase Inhibitors | PIM1, PIM2, PIM3 | ATM 466/4885PPM1D 263/4885VHL 74/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.